medigraphic.com

2022, Number 2

<< Back

Rev Cuba Endoc 2022; 33 (2)

Clinical variability in polycystic ovary syndrome

Cabrera GM, Monteagudo PG, Acosta CA, Vázquez NJC, Ovies CG

Language: Spanish
References: 39
Page:
PDF size: 190.63 Kb.


ABSTRACT

Introduction: Polycystic ovary syndrome (PCOS) is the most common form of chronic anovulation related to androgen excess. The prevalence ranges according to the diagnostic criteria used between 4-21%.
Objective: To describe the clinical characteristics of patients with polycystic ovary syndrome.
Methods: The consensuses and original articles of the last 10 years were selected, which were available in the following search engines: Pubmed, Medscape, Scielo, and Bireme. Other publications that due to their clinical importance have not been replicated were considered.
Conclusions: The variety of phenotypes present in the polycystic ovary syndrome makes the clinical manifestations and risk factors for other morbidities heterogeneous. The influence exerted also by its etiopathogenesis, not completely elucidated, causes the diagnosis and therefore the current management of these patients to have a multidisciplinary approach which is individualized and focused on the priorities and nonconformities that may affect the patients’ quality of life.


REFERENCES

  1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774-800. DOI: https://doi.org/10.1210/edrv.18.6.03181.

  2. Chiliquinga S, Aguirre R, Agudo M, Chú Á, Cuenca S. Criterios diagnósticos y tratamiento integral terapéutico del síndrome de ovarios poliquísticos. Rev Cubana Obstet Ginecol. 2017 [acceso: 29/10/2021];43(3):173-81. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2017000300018&lng=es2.

  3. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6-15. DOI: https://doi.org/10.1016/j.fertnstert.2016.05.0033.

  4. Jamilian M, Foroozanfard F, Kavossian E, Aghadavod E, Shafabakhsh R, Hoseini, et al. Effects of cucumin on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition ESPEN. 2020;36:128-33. DOI: https://doi.org/10.1016/j.clnesp.2020.01.0054.

  5. Lujan ME, Chizen DR, Pierson RA. Diagnostic Criteria for Polycystic Ovary Syndrome: Pitfalls and Controversies. J Obstet Gynaecol Can. 2008;30(8):671-9. DOI: https://doi.org/10.1016/S1701-2163(16)32915-25.

  6. Zore T, Joshi N, Lizneva D, Azziz R. Polycystic ovarian syndrome: long-term health consequences. Semin Reprod Med. 2017;35:271-28. DOI: https://doi.org/10.1055/s-0037-16035696.

  7. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Androgen Excess Society. Positions statement: criteria for de?ning polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45. DOI: https://doi.org/10.1210/jc.2006-01787.

  8. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38.e25. DOI: https://doi.org/10.1016/j.fertnstert.2011.09.0248.

  9. González R, Díaz A, Trimiño L, Suárez GA, Guardarrama L, Acosta FA. Hyperandrogenism and metabolic disorders among women with polycystic ovary syndrome. Rev Cubana Endocrinol. 2018;29(3):1-11. DOI: http://dx.doi.org/10.1016/j.fertnstert.2017.06.0269.

  10. Discacciati V. Síndrome de ovario poliquístico. Evid Actual Pract Ambul. 2007 [acceso: 29/10/2021];10(6):178-80. Disponible en: https://www.scribd.com/document/63846891/Ovario-Poliquistico10.

  11. Roldan MB, Echevarría F. Hiperandrogenismo ¿Qué hacer? Caso clínico. ADOLESCER. 2015 [acceso: 29/10/2021];2(3). Disponible en: https://www.adolescenciasema.org/ficheros/REVISTA%20ADOLESCERE/vol3num3/Adolescere%202015-3.pdf11.

  12. Acosta A, Monteagudo G, Menocal A. Patrón hormonal de mujeres con diagnóstico clínico y ecográfico del síndrome de ovarios poliquísticos. Rev Cubana Endocrinol. 2004 [acceso: 29/10/2021];15(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532004000200003&lng=es12.

  13. Trikudanathan S. Polycystic Ovarian Syndrome. Med Clin N Am. 2015;221-35. DOI: http://dx.doi.org/10.1016/j.mcna.2014.09.00313.

  14. ESHRE/ASRM. Consensus on women's health aspects of polycystic ovary syndrome (PCOS) The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Human Reproduction. 2012;27(1):14-24. DOI: https://doi.org/10.1093/humrep/der39614.

  15. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. The current description and future need for multidisciplinary PCOS. Review. Clinics J Clin Med. 2018;7(11):395. DOI: https://doi.org/10.3390/jcm711039515.

  16. Ovies G, Domínguez E, Verdeja OL, Zamora H. Frecuencia y características clínicas, hormonales y ultrasonográficas sugestivas de síndrome de ovarios poliquísticos en un grupo de mujeres con síndrome metabólico. Rev Cubana Endocrinol. 2008 [acceso: 29/10/2021];19(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532008000100004&lng=es16.

  17. Vázquez JC, Calero JL, Carías JP, Monteagudo G. Correspondencia clínica, hormonal y ecográfica en el diagnóstico del síndrome de ovarios poliquístico. Rev Cubana Endocrinol. 2016 [acceso: 29/10/2021];27(1):4-17. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532016000100002&lng=es17.

  18. Alsamari S, Adams JM, Murphy MK, Hayden DL, Hall JE. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol. 2009;94:4961-70. DOI: https://doi.org/10.1210/jc.2009-083918.

  19. Winter SJ, Talbott E, Guzick DS. Serum testoterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril. 2000;73(4):724-9. DOI: https://doi.org/10.1016/S0015-0282(99)00641-X19.

  20. Legri RS, Arslanian SA, Ehmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical Practice guideline. J Clin Endocrinol Metab. 2013;98:4565-92. DOI: https://doi.org/10.1210/jc.2013-235020.

  21. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev. 2000;21:347-62. DOI: https://doi.org/10.1210/edrv.21.4.040121.

  22. Sekhon A, Zergham A, Tserenpil G, Mebasher A, Malik BH. The association between polycystic ovary syndrome and its dermatological manifestations. Cureus. 2020;12(2):e6855. DOI: https://doi.org/10.7759/cureus.685522.

  23. Orfanos CE. Antiandrógenos en dermatología. Arch Arg Dermatol. 1982;32(Supl. I):51-5. DOI: https://doi.org/10.1159/00005326723.

  24. Velásquez N, Fernández M, Briñez N. Manifestaciones dermatológicas del síndrome de ovario poliquístico. Rev Obstet Ginecol Venez. 2011 [acceso: 29/10/2021];71(4). Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0048-77322011000400007&lng=es24.

  25. González F. Tratamiento del síndrome de ovario poliquístico. Manejo dermatológico. En: Bajares de Lilue M, Pizzi R, Velásquez-Maldonado E, editores. Consenso venezolano de Síndrome de Ovario Poliquístico 2007. Ateproca. 2007 [acceso: 29/10/2021]. Disponible en: https://www.academia.edu/14344304/Consenso_Venezolano_de_S%C3%ADndrome_de_Ovario_Poliqu%C3%ADstico25.

  26. De Ugarte CM, Woods KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006;91(4):1345-50. DOI: https://doi.org/10.1210/jc.2004-230126.

  27. March WA, Moore VM, Wilson KJ, Phillips DI, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544-51. DOI: https://doi.org/10.1093/humrep/dep39927.

  28. Willis SK, Mathew HM, Wise LA, Hatch EE, Wesselink AK, Rothman KJ. Menstrual pattern and self-reported hirsutism as assessed via the modified Ferriman-Gallwy sacle: a cross-sectional estudy. European Journal of Obstetrics Gynecology and Reproductive Biology. 2020;248:137-43. https://doi.org/10.1016/j.ejogrb.2020.03.01228.

  29. Conway GS, Dewailly D, Diamanti-Kandarakis E. The polycystic ovary syndrome: an endocrinologic a perspective from the European Society on Endocrinology. Eur J Endocrinol. 2014;17(14):489-98. DOI: https://doi.org/10.1530/EJE-14-025229.

  30. De Ugarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance, in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454-60.

  31. García Y, Monteagudo G, Padrón RS, González R. Evaluación de la sensibilidad a la insulina en el síndrome de ovarios poliquísticos. Rev Cubana Endocrinol. 2009;20(3):131-40.

  32. Valkenburg O, Steegers-Theunissen R, Smedts H, Dallinga-Thie GM, Fauser B, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:470-6. DOI: https://doi.org/10.1210/jc.2007-175632.

  33. Berneis K, Rizzo M, Lazzaroni V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low- density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:186-9. DOI: https://doi.org/10.1210/jc.2006-170533.

  34. Essah PA, Nestler JE, Carmina E. Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. J Endocrinol Invest. 2008;3:35-41. DOI: https://doi.org/10.1007/BF0334556434.

  35. García Y, Monteagudo G, Padrón RS, González R. Evaluación de las alteraciones lipídicas en el síndrome de ovarios poliquísticos y su relación con la resistencia a la insulina. Rev Cubana Endocrinol. 2010;21(2)145-53.

  36. Schwimmer JB, Khorram O, Chiu V. Abnormal aminotransferasa activity in women with polycystic ovary syndrome. Fertil Steril. 2005:83(2):494-7. DOI: https://doi.org/10.1016/j.fertnstert.2004.08.02036.

  37. Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reprod. 2011;26(9):2442-51. DOI: https://doi.org/10.1093/humrep/der19737.

  38. Shakerardekani Z, Nasehi A, Eftekhar T, Ghaseminezhad A. Ardekani MA, Raisi F. Evaluation of depression and mental health status in women with poly cystic ovary syndrome. J Fam Reprod Health. 2011 [acceso: 29/10/2021];5:67-71. Disponible en: http://jfrh.tums.ac.ir/index.php/jfrh/article/view/12438.

  39. Stratakis CA, Karl M, Schulte HM, Chrousos GP. Glucocorticosteroid resistance in humans. Elucidation of the molecular mechanisms and implications for pathophysiology. Ann N Y Acad Sci. 1994;746:362-74.




2020     |     www.medigraphic.com